Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Berinert in Hereditary Angioedema
NCT00292981Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Aug 2005
- Primary completion
- Feb 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of c1-esterase inhibitor in hereditary angioedema (HAE), sponsored by CSL Limited. Primary endpoint: Time to Start of Relief of Symptoms From HAE Attack at 24 hours. Started Aug 2005; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT00292981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00292981.